Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Where and How to Find Co-Occurrences in Disease Biology Research

Posted on July 29th, 2016 by

Chemistry

R_D_Solutions_Blog_Zeros_Ones_DIGITAL

In research, a co-occurrence refers to two linked concepts appearing within one sentence. In disease biology, a good example would be a sentence with facts that link a protein to a disease, biological functions or other proteins. Continue reading “Where and How to Find Co-Occurrences in Disease Biology Research” »

How Much Can Text-Mining Tools Achieve?

Posted on July 25th, 2016 by

Chemistry

phone-1052022_1920

Text mining has become an essential tool in the arsenal of disease biologists, medicinal chemists and other drug developers. There simply isn’t the time for a researcher to read all the relevant published literature to find answers— Continue reading “How Much Can Text-Mining Tools Achieve?” »

Qualification, Validation, and Fit-for-Purpose Biomarkers

Posted on July 22nd, 2016 by

Pharma R&D

ball-63527_1280

As drug developers we rely greatly on biomarkers for providing information to our drug development programs and supporting submission to regulators.  Continue reading “Qualification, Validation, and Fit-for-Purpose Biomarkers” »

Precompetitive collaboration: Transforming innovation in drug discovery & development

Posted on July 21st, 2016 by

Pharma R&D

R_D_Solutions_Blog_Uncharted_DIGITAL

In 2013, Barbara Mittleman, former director of the Public-Private Partnership Program at the US National Institutes of Health and colleagues assessed the status of precompetitive consortia. Continue reading “Precompetitive collaboration: Transforming innovation in drug discovery & development” »

A gathering of global perspectives… a look at DIA’s annual meeting: Post 2 of 2

Posted on July 18th, 2016 by

Pharma R&D

DIA

As referenced in my last post, the Drug Information Association (DIA), held its annual conference in Philadelphia at the end of June with this year’s theme being “A Gathering of Global Perspectives.” In follow-up to that post, I want to share with you what I gleaned from two additional noteworthy sessions. Continue reading “A gathering of global perspectives… a look at DIA’s annual meeting: Post 2 of 2” »

When drugs collide ….

Posted on July 15th, 2016 by

Pharmacovigilance

R_D_Solutions_Blog_Unseen_DIGITAL

Pharmaceutical companies increasingly are adopting “proactive pharmacovigilance” and other strategies to help ensure the safety of a new entity as early as possible in the discovery/development process. Continue reading “When drugs collide ….” »

  1. 1
  2. …
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47
  8. …
  9. 60


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.